跳至主要内容
临床试验/NCT00000758
NCT00000758已完成3 期

A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women

National Institute of Allergy and Infectious Diseases (NIAID)21 个研究点 分布在 2 个国家目标入组 158 人开始时间: 2001年8月31日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
158
试验地点
21

研究概览

简要总结

To determine the efficacy and safety of intravaginal fluorouracil administered as prophylaxis in HIV-infected women who have received standard ablative therapy (surgery) for high-grade cervical dysplasia (pre-cancer of the cervix; cervical intraepithelial neoplasia). To correlate time to recurrence of cervical dysplasia with T-cell function.

Women with HIV infection are at greater risk for cervical dysplasia. Because of the likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer, there is an urgent need to develop appropriate therapies.

详细描述

Women with HIV infection are at greater risk for cervical dysplasia. Because of the likelihood that untreated or recurrent cervical dysplasia may progress to invasive cancer, there is an urgent need to develop appropriate therapies.

Patients are randomized to receive either intravaginal fluorouracil or no treatment (observation only). Fluorouracil cream is self-administered via applicator at biweekly intervals for 6 months. Patients are evaluated for recurrent cervical dysplasia by cytology and colposcopy with or without biopsy.

研究设计

研究类型
Interventional
干预模型
Parallel
主要目的
Prevention

入排标准

年龄范围
13 Years 至 —(Child, Adult, Older Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Concurrent Medication:
  • •Antiretrovirals (AZT, ddI, ddC) and immunomodulators (interferon and interleukin).
  • •Prophylaxis or treatment for opportunistic infections.
  • •Vaginal antifungal agents or other indicated vaginal medications (although not permitted on day of fluorouracil application).
  • •Contraceptives.
  • •Acyclovir (prophylaxis or treatment) in patients with a history of primary or recurrent genital herpes.
  • •Patients must have:
  • •HIV infection.
  • •Prior cervical dysplasia (grade II or III cervical intraepithelial neoplasia) successfully treated with an ablative procedure within the past 12 weeks.
  • •Patients less than 18 years of age must have consent of parent or guardian.

排除标准

  • •Co-existing Condition:
  • •Patients with the following symptoms and conditions are excluded:
  • •Untreated or persistent vaginal or vulvar dysplasia.
  • •Colposcopy or biopsy inconclusive or positive for dysplasia.
  • •Active genital ulcerative disease such as syphilitic chancre or herpes ulcer.
  • •Adenocarcinoma in situ.
  • •Concurrent Medication:
  • •Cytotoxic chemotherapy for malignancy.
  • •High-dose steroids (> 10 mg/day prednisone or its steroid equivalent).
  • •Patients with the following prior conditions are excluded:
  • •Malignancy requiring cytotoxic chemotherapy within the 3 months prior to study entry.
  • •Prior hysterectomy.
  • •History of allergic reaction or severe hypersensitivity to fluorouracil.
  • •Prior Medication:
  • •Fluorouracil (systemic or topical) within 3 months prior to study entry.

研究者

申办方类型
Nih
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验